The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium
Lynda M. Vrooman(Boston Children's Hospital), Stephen E. Sallan, Luis A. Clavell(San Juan City Hospital), Eric Larsen(University of Massachusetts Chan Medical School), Cindy L. Schwartz(Brown University), Uma H. Athale(McMaster University), Lewis B. Silverman(Columbia University Irving Medical Center), Peter D. Cole(Rutgers, The State University of New Jersey), Barbara L. Asselin(University of Rochester Medical Center), Bruno Michon(Centre hospitalier universitaire de Québec), Steven E. Lipshultz(Jacobs Institute), Caroline Laverdière(Centre Hospitalier Universitaire Sainte-Justine), Kara M. Kelly(Roswell Park Comprehensive Cancer Center), Kristen E. Stevenson(Dana-Farber Cancer Institute), Donna Neuberg(Otsuka (Japan)), Harvey J. Cohen(Lucile Packard Children's Hospital), Marshall A. Schorin(Inova Fairfax Hospital)
Cited by 117
Related Papers
Chronic Health Conditions in Adult Survivors of Childhood Cancer
|New England Journal of Medicine|2006|3.6k
Analysis of <i>Fusobacterium</i> persistence and antibiotic response in colorectal cancer
|Science|2017|1.6k